search
Back to results

Cryoneurolysis for Facet Mediated Chronic Low Back Pain

Primary Purpose

Low Back Pain, Facet Joint Pain

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
iovera system
Radiofrequency ablation
Sponsored by
Medical Pain Management Services, PLLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Low Back Pain focused on measuring low back pain

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male or female volunteers, at least 18 years of age at screening Primary complaint of axial low-back pain suggestive of unilateral or bilateral facet joint involvement (i.e., facet mediated CLBP) Low back pain is chronic (i.e., > 3 months' duration) Low back pain score of ≥ 4 (i.e., moderate pain) on the 0 to 10 NRS or functional impairment at screening Successful trial of two diagnostic medial branch blocks consisting of two positive blocks with local anesthetic only (i.e., no steroids) that results in at least 50% relief of primary (index) pain for the duration of the local anesthetic used or history of a positive response to prior radiofrequency treatment (i.e., ≥ 6 months prior to enrollment) Failure of at least three months of conservative non-operative therapy (e.g., physical therapy, chiropractic care, spinal injections, NSAIDs or other appropriate analgesics), Able to provide informed consent, adhere to the study visit schedule, and complete all study assessments Exclusion Criteria: Active workers' compensation, personal injury, Social Security disability insurance (SSDI), or other litigation/compensation related to the spine Serious spinal disorders (verified on magnetic resonance imaging (MRI)) that may impact outcomes, including any of the following: Suspected cauda equina syndrome (e.g., bowel/bladder dysfunction) Infection Tumor Traumatic fracture Systemic inflammatory spondyloarthropathy Lumbar radiculopathy/radiculitis (i.e., root irritation and deficit) Neurogenic claudication Prior lumbar spinal fusion surgery Comorbidity that, in the judgment of the Investigator, may affect the subject's ability to participate in the study including lumbar radiculopathy and neuropathic pain disorder Currently pregnant, nursing, or planning to become pregnant during the study Known contraindication to study devices, including any of the following: Cryoglobulinemia Paroxysmal cold hemoglobinuria Cold urticaria Raynaud's disease Open and/or infected wounds at or near the treatment site Coagulopathy 3.5-inch needle cannot be used in the low back region because of habitus Severe chronic pain disorder that in the opinion of the investigator may impact postsurgical outcomes Presence of any of the following: Spinal neurostimulator Intrathecal analgesic drug pump Current manifestation of poorly controlled mental illness that in the opinion of the investigator may meaningfully impact treatment outcomes, including any of the following: Mood disorder (e.g., major depression, bipolar) Psychotic disorder (e.g., schizophrenia) Subject received other spine intervention/therapies in the 30 days prior to block administration (e.g., spinal injections, minimally invasive therapies, surgical therapies) Subject received radiofrequency ablation in the low back region ≤ 6 months before study enrollment History, suspicion, or clinical manifestation of: Alcohol abuse or dependence Illicit drug use Opioid abuse or dependence (≥40 mg MED PO/day in past 30 days) Given the COVID-19 pandemic, the subject must be medically fit/cleared for treatment by the investigator. If there is a concern about a subject's recent or potential exposure to COVID-19, or if the subject is not medically fit/cleared for treatment due to suspected COVID-19 illness/symptoms (or other serious illness), the subject must be excluded per Exclusion criterion #4.

Sites / Locations

  • The Albany & Saratoga Centers For Pain Management

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Cryoneurolysis

Radiofrequency ablation

Arm Description

Subjects will receive iovera° cryoneurolysis to the medial branch nerves of the lumbar spine

Subjects will receive RFA to the medial branch nerves of the lumbar spine

Outcomes

Primary Outcome Measures

Safety of cryoneurolysis as compared to radiofrequency ablation (RFA)
Safety will be assessed as the number of subjects with reported treatment-related adverse related to cryoneurolysis or RFA.

Secondary Outcome Measures

Change in pain intensity as measured by 11-point Numeric Rating Scale (NRs)
Subjects will evaluate their pain in the low back region using an 11-point Numeric Rating Scale (NRS), where 0=no pain and 10=worst possible pain. Subjects will evaluate how much pain they are currently experiencing and their worst and average level of pain over the past 24 hours.

Full Information

First Posted
August 21, 2023
Last Updated
August 23, 2023
Sponsor
Medical Pain Management Services, PLLC
Collaborators
Pacira Pharmaceuticals, Inc
search

1. Study Identification

Unique Protocol Identification Number
NCT06016127
Brief Title
Cryoneurolysis for Facet Mediated Chronic Low Back Pain
Official Title
A Single-center, Randomized, Pilot Study to Assess Iovera° Lumbar Medial Branch Cryoneurolysis vs Lumbar Radiofrequency Ablation for Facet Mediated Chronic Low Back Pain
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
June 18, 2022 (Actual)
Primary Completion Date
October 23, 2023 (Anticipated)
Study Completion Date
October 23, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medical Pain Management Services, PLLC
Collaborators
Pacira Pharmaceuticals, Inc

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a single-center, randomized, pilot study in adult subjects with facet mediated CLBP. Thirty (30) subjects are planned for initial enrollment and will be randomized 1:1 to receive ioveraº medial branch cryoneurolysis or radiofrequency ablation.
Detailed Description
This is a single-center, randomized, pilot study in adult subjects with facet mediated CLBP. Thirty (30) subjects are planned for initial enrollment and will be randomized 1:1 to receive ioveraº medial branch cryoneurolysis or radiofrequency ablation. This study is designed to determine if a full efficacy RCT can be successfully conducted using the procedures and protocols described in the current pilot study protocol, or if protocol modifications are necessary before moving forward with a full efficacy RCT. Furthermore, the study will assess the feasibility of the outcome measurements employed, construct a foundation for sample size calculation, and the acceptability/practicality of conducting the full efficacy RCT. Randomization to treatment groups according to the randomization assignment will be performed on the day of treatment. The treatment groups are: Group 1: subjects will receive iovera° cryoneurolysis to the medial branch nerves of the lumbar spine Group 2: subjects will receive RFA to the medial branch nerves of the lumbar spine

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Low Back Pain, Facet Joint Pain
Keywords
low back pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomization to treatment groups according to the randomization assignment
Masking
None (Open Label)
Masking Description
Open label
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cryoneurolysis
Arm Type
Active Comparator
Arm Description
Subjects will receive iovera° cryoneurolysis to the medial branch nerves of the lumbar spine
Arm Title
Radiofrequency ablation
Arm Type
Active Comparator
Arm Description
Subjects will receive RFA to the medial branch nerves of the lumbar spine
Intervention Type
Device
Intervention Name(s)
iovera system
Other Intervention Name(s)
iovera
Intervention Description
The iovera° system consists of a reusable, portable Handpiece, along with single patient use sterile Smart Tips (i.e., cryoprobes) and disposable nitrous oxide (N2O) cartridges. The iovera° system produces the desired effect through initiation of a cooling cycle. Each cooling cycle is initiated by fully inserting the Smart Tip into the selected procedure site and activating the cryogen flow. The Smart Tip needles are made of stainless steel and have a closed tip, fully enclosing the cryogen. The "190" Smart Tip will be used in this study.
Intervention Type
Device
Intervention Name(s)
Radiofrequency ablation
Intervention Description
The RFA system consists of a Cosman, G4 Generator. The needles used are 20-gauge, 10cm long with a 10mm active tip manufactured by Cosman. A grounding pad, also manufactured by Cosman, is placed on the upper thigh for each procedure and connected to the G4 Generator.
Primary Outcome Measure Information:
Title
Safety of cryoneurolysis as compared to radiofrequency ablation (RFA)
Description
Safety will be assessed as the number of subjects with reported treatment-related adverse related to cryoneurolysis or RFA.
Time Frame
0-12 months
Secondary Outcome Measure Information:
Title
Change in pain intensity as measured by 11-point Numeric Rating Scale (NRs)
Description
Subjects will evaluate their pain in the low back region using an 11-point Numeric Rating Scale (NRS), where 0=no pain and 10=worst possible pain. Subjects will evaluate how much pain they are currently experiencing and their worst and average level of pain over the past 24 hours.
Time Frame
0-12 months
Other Pre-specified Outcome Measures:
Title
Change in functional disability
Description
Function disability will be measured by the Oswestry Disability Index. The score ranges from 0-50, with lower scores reflecting milder disability.
Time Frame
0-12 months
Title
Change in Patients' Global Impression of Change
Description
The Patients' Global Impression of Change (PGIC) is a 7-point patient self-reporting scale of overall change in activity limitations, symptoms, emotions, and quality of life ranging from 1) no change 2) hardly any change 3) no noticeable change 4) change has not made any real difference 5) a slight but noticeable change 6) a definite improvement 7) considerable improvement. The scale also assesses degree of change since beginning care (0=much better, 10=much worse).
Time Frame
0-12 months
Title
Satisfaction with pain management
Description
Subject satisfaction with pain management as measured on a scale ranging from 1) extremely dissatisfied 2) dissatisfied 3) neither satisfied nor dissatisfied 4) satisfied 5) extremely satisfied.
Time Frame
0-12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female volunteers, at least 18 years of age at screening Primary complaint of axial low-back pain suggestive of unilateral or bilateral facet joint involvement (i.e., facet mediated CLBP) Low back pain is chronic (i.e., > 3 months' duration) Low back pain score of ≥ 4 (i.e., moderate pain) on the 0 to 10 NRS or functional impairment at screening Successful trial of two diagnostic medial branch blocks consisting of two positive blocks with local anesthetic only (i.e., no steroids) that results in at least 50% relief of primary (index) pain for the duration of the local anesthetic used or history of a positive response to prior radiofrequency treatment (i.e., ≥ 6 months prior to enrollment) Failure of at least three months of conservative non-operative therapy (e.g., physical therapy, chiropractic care, spinal injections, NSAIDs or other appropriate analgesics), Able to provide informed consent, adhere to the study visit schedule, and complete all study assessments Exclusion Criteria: Active workers' compensation, personal injury, Social Security disability insurance (SSDI), or other litigation/compensation related to the spine Serious spinal disorders (verified on magnetic resonance imaging (MRI)) that may impact outcomes, including any of the following: Suspected cauda equina syndrome (e.g., bowel/bladder dysfunction) Infection Tumor Traumatic fracture Systemic inflammatory spondyloarthropathy Lumbar radiculopathy/radiculitis (i.e., root irritation and deficit) Neurogenic claudication Prior lumbar spinal fusion surgery Comorbidity that, in the judgment of the Investigator, may affect the subject's ability to participate in the study including lumbar radiculopathy and neuropathic pain disorder Currently pregnant, nursing, or planning to become pregnant during the study Known contraindication to study devices, including any of the following: Cryoglobulinemia Paroxysmal cold hemoglobinuria Cold urticaria Raynaud's disease Open and/or infected wounds at or near the treatment site Coagulopathy 3.5-inch needle cannot be used in the low back region because of habitus Severe chronic pain disorder that in the opinion of the investigator may impact postsurgical outcomes Presence of any of the following: Spinal neurostimulator Intrathecal analgesic drug pump Current manifestation of poorly controlled mental illness that in the opinion of the investigator may meaningfully impact treatment outcomes, including any of the following: Mood disorder (e.g., major depression, bipolar) Psychotic disorder (e.g., schizophrenia) Subject received other spine intervention/therapies in the 30 days prior to block administration (e.g., spinal injections, minimally invasive therapies, surgical therapies) Subject received radiofrequency ablation in the low back region ≤ 6 months before study enrollment History, suspicion, or clinical manifestation of: Alcohol abuse or dependence Illicit drug use Opioid abuse or dependence (≥40 mg MED PO/day in past 30 days) Given the COVID-19 pandemic, the subject must be medically fit/cleared for treatment by the investigator. If there is a concern about a subject's recent or potential exposure to COVID-19, or if the subject is not medically fit/cleared for treatment due to suspected COVID-19 illness/symptoms (or other serious illness), the subject must be excluded per Exclusion criterion #4.
Facility Information:
Facility Name
The Albany & Saratoga Centers For Pain Management
City
Saratoga Springs
State/Province
New York
ZIP/Postal Code
12866
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Contact PI

Learn more about this trial

Cryoneurolysis for Facet Mediated Chronic Low Back Pain

We'll reach out to this number within 24 hrs